A Double‐Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD

Yeh, Mary Sau Ling; Mari, Jair J.; Costa, Mariana Caddrobi Pupo; Andreoli, Sérgio Baxter; Bressan, Rodrigo A.; Mello, Marcelo Feijó de

doi:10.1111/j.1755-5949.2010.00188.x

Cited by 54 publications

(57 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topiramate's effects on PTSD symptom severity are also supportive of the promising findings of prior studies that examined participants with PTSD but without AUD (Lindley et al, 2007, Tucker et al, 2007, Yeh et al, 2011). …”

Section: Discussionsupporting

confidence: 74%

“…Topiramate has shown partial effectiveness in reducing PTSD symptoms in patients without AUD in three open trials (Berlant and van Kammen, 2002, Berlant, 2004, Alderman et al, 2009) and three small-to-medium sized controlled trials (Lindley et al, 2007, Tucker et al, 2007, Yeh et al, 2011). In a placebo-controlled trial in veterans, topiramate treatment was associated with greater improvement in PTSD re-experiencing symptoms when used to augment standard PTSD pharmacotherapy, although with more adverse effects and higher dropout (Lindley et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Topiramate also showed significantly greater reductions in PTSD re-experiencing symptoms than placebo in non-veterans with PTSD (Tucker et al, 2007). The most recent of the controlled trials in a civilian sample found that topiramate significantly reduced PTSD symptom severity as compared to placebo, with particular effectiveness in reducing re-experiencing and avoidance/numbing symptom clusters (Yeh et al, 2011). …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Topiramate Treatment of Alcohol Use Disorder in Veterans with Posttraumatic Stress Disorder: A Randomized Controlled Pilot Trial

Batki

Pennington

Lasher

et al. 2014

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

Background The course of posttraumatic stress disorder (PTSD) is frequently and severely complicated by co-occurring alcohol use disorder (AUD), yet there are few reports of pharmacologic treatments for these co-morbid conditions. The objective of this pilot study was to obtain a preliminary assessment of the efficacy and safety of topiramate in reducing alcohol use and PTSD symptoms in veterans with both disorders. Methods This was a prospective 12-week, randomized, double-blind, placebo-controlled pilot trial of flexible-dose topiramate up to 300mg/day in 30 veterans with PTSD and AUD. The primary outcome measure was frequency of drinking. Secondary outcomes consisted of other measures of alcohol use and PTSD symptom severity. Results Within-group analyses showed that topiramate treatment was associated with significant reductions in frequency and amount of alcohol use and alcohol craving from baseline through week 12. Between-group analyses showed that topiramate reduced frequency of alcohol use and alcohol craving significantly more than placebo and tended to reduce drinking amount. Topiramate treatment was also associated with decreased PTSD symptom severity and tended to reduce hyperarousal symptoms compared to placebo. Topiramate transiently impaired learning and memory, with significant recovery by the end of treatment. Conclusions These preliminary results indicate that in veterans with co-occurring PTSD and AUD, topiramate may be effective in reducing alcohol consumption, alcohol craving, and PTSD symptom severity – particularly hyperarousal symptoms.. Topiramate was associated with transient cognitive impairment but was otherwise well tolerated.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Topiramate Treatment of Alcohol Use Disorder in Veterans with Posttraumatic Stress Disorder: A Randomized Controlled Pilot Trial

Batki

Pennington

Lasher

et al. 2014

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

“…There is also evidence for the efficacy of the antipsychotics risperidone (Padala et al, 2006), olanzapine (Carey et al, 2012) and the anticonvulsant topiramate; (Yeh et al, 2011). Medications which have not been found efficacious in placebo-controlled trials include citalopram, alprazolam, and the anticonvulsants tiagabine and divalproex.…”

Section: Acute Treatment Of Post-traumatic Disordermentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

“…In a systematic review, two small trials (<40 patients in each) used topiramate as monotherapy, and showed no significant difference between the groups on PTSD symptom severity 24,25…”

Section: Pharmacological Treatment Of Ptsdmentioning

confidence: 99%

Management of adults with PTSD part II: drugs and other interventions

2014

DTB

View full text Add to dashboard Cite

Exposure to traumatic events is common, and many people experience some symptoms following such exposure. In most people, these symptoms subside within a few weeks, but for others, post-traumatic stress disorder (PTSD) develops and may be long-lasting. Part I of this article (DTB 2014; 52: 33-6) discussed the recognition of PTSD and evidence for trauma-focused psychological treatment (generally considered to be first-line treatment). Here in part II of the article, we discuss other possible second-line options: pharmacological treatments and other therapies.

show abstract

A Double‐Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD

Abstract: Topiramate was effective in improving reexperiencing and avoidance/numbing symptom clusters in patients with PTSD. This study supports the use of anticonvulsants for the improvement of symptoms of PTSD.

Cited by 54 publications

References 20 publications

Topiramate Treatment of Alcohol Use Disorder in Veterans with Posttraumatic Stress Disorder: A Randomized Controlled Pilot Trial

Topiramate Treatment of Alcohol Use Disorder in Veterans with Posttraumatic Stress Disorder: A Randomized Controlled Pilot Trial

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Management of adults with PTSD part II: drugs and other interventions

Contact Info

Product

Resources

About